2015 American Society of Clinical Oncology Annual Meeting*

May 29-June 2, 2015; Chicago, Illinois
Sagar Lonial, MD, Jeff P. Sharman, MD, Julie M. Vose, MD, MBA, and Farhad Ravandi-Kashani, MD, review data from key hematologic malignancy presentations from the 2015 clinical oncology meeting in Chicago. Topics include multiple myeloma, indolent non-Hodgkin’s Lymphoma, chronic lymphocytic leukemia, acute leukemia, and myelodysplasias.
person default
Sagar Lonial, MD
person default
Farhad Ravandi, MD
Jeff P. Sharman, MD
Julie M. Vose, MD, MBA

Hematologic Malignancies

Investigators found 3 distinct stem cell phenotypes in AML with no leukemia-free survival at 2 years in those with ALDHhigh phenotype without a bone marrow transplant.

Released: June 5, 2015

Inheritance of a lower number of activating KIR genes in NK cells associated with increased risk of developing high-risk MDS.

Released: June 5, 2015

Doses of gilteritinib ≥ 80 mg showed an ORR of 58% in patients with relapsed/refractory AML and the FLT3 mutation.

Released: June 5, 2015

CD19-targeted 19-28ζ CAR T-cell therapy produced a high CR rate in adult patients with relapsed/refractory ALL.

Released: June 5, 2015

Results of an open-label phase III trial investigating the safety and efficacy of adding idelalisib to ofatumumab in pretreated CLL.

Released: June 5, 2015

Results of a prospectively designed meta-analysis of a new surrogate endpoint that may expedite patient access to effective new therapies.

Released: June 5, 2015

In patients with previously untreated high-intermediate–risk or high-risk DLBCL, brentuximab vedotin + R-CHOP was associated with a response rate of 80%.

Released: June 5, 2015

Results from a randomized phase III trial investigating the addition of the mAB elotuzumab to lenalidomide and dexamethasone in patients with relapsed/refractory MM.

Released: June 5, 2015

Results from the first head-to-head phase III trial comparing 2 proteasome inhibitors in multiple myeloma.

Released: June 5, 2015

Phase II study evaluating induction regimen of KRd, followed by ASCT, KRd consolidation, and maintenance in newly diagnosed multiple myeloma.

Released: June 5, 2015

In this continuation of a phase I/II trial, the optimized dose and schedule of panobinostat and carfilzomib was associated with promising responses in relapsed/refractory multiple myeloma.

Released: June 5, 2015

Overall response rates of 50% in DLBCL and 100% in follicular lymphoma; all CRs maintained as of last analysis.

Released: June 5, 2015

Retrospective analysis suggests that subsets of patients with FL may receive suboptimal doses of rituximab.

Released: June 5, 2015

Sagar Lonial, MD; Farhad Ravandi, MD; Jeff P. Sharman, MD; and Julie M. Vose, MD, MBA, discuss the clinical relevance of key findings in hematologic malignancies presented at the 2015 American Society of Clinical Oncology annual meeting.

person default Sagar Lonial, MD person default Farhad Ravandi, MD Jeff P. Sharman, MD Julie M. Vose, MD, MBA Physicians: maximum of 2.75 AMA PRA Category 1 Credits Released: August 25, 2015 Expiration: August 24, 2016

In this downloadable slideset, Sagar Lonial, MD, Farhad Ravandi, MD, Jeff P. Sharman, MD, and Julie M. Vose, MD, MBA, discuss the clinical relevance of key findings in hematologic malignancies presented at the 2015 American Society of Clinical Oncology annual meeting.

Released: August 25, 2015

New phase III results from the HELIOS trial of ibrutinib plus BR in previously treated CLL/SLL.

Released: June 5, 2015

In this phase III study, pacritinib demonstrated significantly reduced total symptom scores and improved overall survival.

Released: June 5, 2015

The obinutuzumab-containing regimen was associated with a significant reduction in the risk of progression or death compared with bendamustine alone in patients with rituximab-refractory indolent NHL.

Released: June 5, 2015

In this population of patients who had received a median of 5 prior therapies over 5 years and were refractory to most available agents, daratumumab was associated with an ORR of 29%; no patients discontinued due to adverse events.

Released: June 5, 2015
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?